Hyperuricemia and the problem of chronic kidney disease

Close metadata

Recommended articles:

Thoracoscopic resection of recurrent atypically located parathyroid adenoma of anterior mediastinum in a patient with hyperparathyroidism undergoing renal replacement therapy. Pirogov Russian Journal of Surgery. 2024;(6):81-87

Digestive system diseases and a chronic kidney disease — the two sides of the healthcare global problems. Russian Journal of Preventive Medicine. 2024;(7):108-113

Clinical consequences of sarcopenic obesity. Part 1. Non-alcoholic fatty liver disease, type 2 diabetes mellitus, chronic kidney disease. Russian Journal of Preventive Medicine. 2024;(8):114-120

Feasibility of application in the practice of dental diseases of metabolic changes in bone tissue in examination of patients with chronic kidney disease. Russian Journal of Stomatology. 2024;(3):16-22

Assessment of risk of developing fractures and sarcopenia and quality of life of patients with chronic kidney disease at the outpatient stage. Russian Journal of Preventive Medicine. 2024;(12):88-91

Recommendations for the rehabilitation of patients with chronic kidney disease requiring hemodialysis (literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6):62-73

Associations between the gut microbiota-derived metabolites with the parameters of 24-hour ambulatory blood pressure monitoring in patients on maintenance hemodialysis. Russian Journal of Preventive Medicine. 2025;(3):96-102

The paper reviews the literature on the role of hyperuricemia as a risk factor for chronic kidney disease and as one of the factors for the progression of existing kidney disease. It gives epidemiological information on a relationship between hyperuricemia and kidney lesion. The mechanisms for the damaging action of uric acid on kidney tissue, which have experimentally and clinically observed, are considered. The main areas of hyperuricemia correction and its place in the total nephroprotection strategy are defined.

Keywords:

hyperuricemia

gout

chronic kidney disease

tubulointerstitial fibrosis

epithelial-mesenchymal transdifferentiation

Authors:

Shcherbak A.V.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka

Kozlovskaia L.V.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

Bobkova I.N.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

SPIN RSCI: 4217-4514

Balkarov I.M.

Kafedra terapii i professional'nykh bolezneĭ mediko-profilakticheskogo fakul'teta Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Lebedeva M.V.

I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Stakhova T.Iu.

Kafedra terapii i professional'nykh bolezneĭ mediko-profilakticheskogo fakul'teta Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

List of references:

Stengel B., Tarver-Carr M.E., Power N.R. et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14: 479.
Haroun M.K., Jaar B.G., Hoffman S.C. et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003; 14: 2934.
Iseki K., Ikemiya Y., Inoue T. et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642.
Bellomo G., Venanzi S., Verdura C. et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010; 56: 264.
Pal'tsev M.A., Varshavskii V.A., Maksimov N.A., Balkarov I.M. Morfologicheskaya kharakteristika giperurikemicheskogo varianta khronicheskogo latentnogo glomerulonefrita. Arkh patol 1988; 6: 8-15.
Mukhin N.A., Shonichev D.G., Balkarov I.M. i dr. Formirovanie arterial'noi gipertonii pri uratnom tubulointerstitsial'nom porazhenii pochek. Ter arkh 1999; 6: 12-24.
Lebedeva M.V., Balkarov I.M., Lukicheva T.I. i dr. Kliniko-diagnosticheskoe znachenie opredeleniya mikroal'buminurii i aktivnosti kanal'tsevogo fermenta N-atsetil-b-D-glyukozaminidazy u lits s giperurikozuriei. Ter arkh 1998; 4: 48-54.
Shcherbak A.V., Balkarov I.M., Kozlovskaya L.V. i dr. Snizhenie fibrinoliticheskoi aktivnosti mochi u patsientov s nasledstvenno obuslovlennym narusheniem obmena mochevoi kisloty. Ter arkh 2001; 6: 8-10.
Hunsicker L.G., Adler S., Caggiula A. et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51: 1908.
Iseki K., Ikemiya Y., Inoue T. et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44 (4): 642-650.
Mazzali M. Uric acid and transplantation. Semin Nephrol 2005; 25: 50-55.
Mukhin N.A., Fomin V.V., Lebedeva M.V. Giperurikemiya kak komponent kardiorenal'nogo sindroma. Ter arkh 2011; 6: 5-12.
Obermayr R.P., Temml C., Gutjahr G. et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19: 2407.
Weiner D.E., Tighiouart H., Elsayed E.F. et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19: 1204.
Chonchol M., Shlipak M.G., Katz R. et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50: 239.
Jalal D.J, Maahs D.M., Hovind P. et al. Uric acid as a mediator of diabetic nephropathy. Semin Nephrol 2011; 31 (5): 459-465.
Yan Huang, Yu-Lin Li, He HuangLing et al. Effects of Hyperuricemia on Renal Function of Renal Transplant Recipients: A Systematic Review and Meta-Analysis of Cohort Studies. PLoS One 2012; 7 (6): e39457.
Johnson R.S., Segal M.S., Sriniivas T. et al. Essencial hypertension, progressive renal disease and uric acid: a pathogenic link? J Am Soc Nephrol 2005; 16: 1990
Baker J.F., Krishnan E., Chen L., Schumacher R. Serum uric acid and CVD: recent developments and where do they lead us? Am J Med 2005; 118: 816.
Ikeda A., Ichikawa K., Ueno Y. et al. The association between serum uric acid and renal damage in a community-based population: the Takahata study. Clin Exp Nephrol 2012 Nov 27. [Epub ahead of print]
Kuo C.F., See L.C., Yu K.H. et al. Significance of serum uric acid levels in the risk of all-cause and cardiovascular mortality. Reumatology (Oxford) 2013; 52: 127.
Niskanen L.K., Laaksonen D.E., Nyyssonen K. et al. Uric acid levels as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 154.
Fang J., Alderman M.N. Serum uric acid and cardiovascular mortality the NHANES I Epidemiologic follow-up study, 1971-1992/ National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404.
Wheeler J.G., Juzwishin K.D., Eiriksdottir G. et al. Serum uric acid and CHD in 9,458 incident cases and 155084 controls: prospective study and meta-analysis. PloS Med 2005; 2: e76
Li Y.L., Wang L., Li J., Huang Y., Yuan W.M. The correlation between uric acid and the incidence and prognosis of kidney diseases: a systematic review and meta-analysis of cohort studies. Zhonghua Nei Ke Za Zhi 2011; 50 (7): 555-561.
Mercuro G., Vitale C. Effect of hyperuricemia upon endotelial function in patients at increased cardiovascular risk. Am J Cardiol 2004; 94: 932-935.
Stakhova T.Yu., Pulin A.A., Lebedeva M.V. i dr. Klinicheskoe znachenie disfunktsii endoteliya u bol'nykh essentsial'noi arterial'noi gipertoniei i uratnym dismetabolizmom s porazheniem pochek. Ter arkh 2011; 10: 10-15.
Sinyutina E.A., Aleksandriya L.G., Trayanova T.G., Moiseev V.S. Giperurikemiya pri khronicheskoi serdechnoi nedostatochnosti. Kardiorenal'nye effekty allopurinola. Klin nefrol 2012; 4: 46-50.
Yamanaka H. Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition. Nucleosides Nucleotides Nucleic Acids 2011; 30: 1018.
Atakhanova L.E., Tsurko V.V., Buleeva I.M. i dr. Podagra: ot etiologii i patogeneza k diagnostike i ratsional'noi farmakoterapii. Sovremen revmatol 2007; 1: 13-18.
Chen C.J., Shi Y., Hearn A. et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated monosodium urate crystals. J Clin Invest 2006; 116 (8): 2262-2271.
Yang Zhou, Li Fang, Lei Jiang et al. Uric Acid Induces Renal Inflammation via Activating Tubular NF kB Signaling Pathway. PLoS One 2012; 7 (6): e39738.
Ryu E.S., Kim M.J., Shin H.S. et al. Uric Acid-induced Phenotypic Transition of Renal Tubular Cells as a Novel Mechanism of Chronic Kidney Disease. Am J Physiol Renal Physiol 2013; 304 (5): F471-480.
Huang W-Y., Li Z-G. RGC-32 Mediates Transforming Growth FactorB2-induced Epithelial-Mesenchymal Transition in Human Renal Proximal Tubular. Cell Biol Chem 2009; 284 (14): 942.
Kim S.M., Choi Y.W., Seok H.Y. et al. Reducing Serum Uric Acid Attenuates TGF-Β(1)-Induced Profibrogenic Progression in Type 2 Diabetic Nephropathy. Arthritis Rheum 2012; 121 (3-4): e109-e121.
Kolz M., Johnson T., Teumer A. et al. Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations. PLoS Genet 2009; 5 (6): e1000504.
Anzai N., Enomoto A. Renal urate handling: clinical relevance of recent advances. Curr Rheumatol Rep 2005; 7 (3): 227-234.
Colin A.J. Farguharson N. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226.
Mazzali M., Kanellis J. Hyperuricemia induces a primary renal arteriolopathy in rats by a BP-independent mechanism. Am J Physiol - Renal Physiol 2002; 282 (561-566): F991-F997.
Khosla U.N., Zharikov S., Finch J.I. et al. Hyperuricemia induces endothelial dysfunction and vasoconstriction. Kidn Intern 2005; 67: 1739-1742.
Li J., Bertram J.F. Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis. Nephrology (Carlton) 2010; 15 (5): 507-512.
Feig D.I., Kang D., Johnson R. Uric acid and CV risk. N Engl J Med 2008; 358: 1811-1821.
Doehner W., Schoene N. Effects of xanthine oxidase inhibition with allopurinol on endothelial dysfunction and periferial blood flow in hyperuricemic patients with heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105 (22): 2619-2624.
Kanbay M., Yilmaz M.I., Sonmez A. et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Kidney Dis 2011; 58 (3): 398-408.
Remuzzi G., Weening J.J. Albuminuria as early test for vascular disease. Lancet 2005; 365: 556-557.
Lebedeva M.V., Balkarov I.M., Mukhin N.A. Rannyaya diagnostika uratnogo porazheniya pochek. Ter arkh 1997; 6: 56-59.
Kozlovskaya L.V., Mukhin N.A., Bobkova I.N. i dr. Znachenie issledovaniya v moche molekulyarnykh mediatorov vospaleniya i fibroza pri khronicheskom glomerulonefrite. Ter arkh 2004; 9: 84-89.
Konta T., Kudo K., Sato H. et al. Albuminuria is an independent predictor of all-cause and CV mortality in the Japanese population: the Takahata Study. Clin Exp Nephrol 2013 Jan 24. [Epub ahead of print]
Goicoechea M., García de Vinuesa S. et al. Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk. Clin J Am Soc Nephrol 2010; 5 (8): 1388-1393.
Wang H., Wei Ykong X., Xu D. Effects of Urate-Lowering Therapy in Hyperuricemia on Slowing the Progression of Renal Function: A Meta-Analysis. J Ren Nutr 2012 Nov 3. pii: S1051-2276(12)00172-0. doi: 10.1053/j.jrn.2012.08.005. [Epub ahead of print].
Siu Y.P., Leung K.T., Tong M.K., Kwan T.H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Ren Fail 2012; 34 (4): 510-520.
George J., Carr E., Davies J. et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-2516.
Feig D.L., Soletsky B. Effect of allopurinol on the BP of adolescents with newly diagnosed essencial hypertension. JAMA 2008; 330: 94-132.
Riegersperger M., Covic A., Goldsmith D. Allopurinol, uric acid, and oxidative stress in cardiorenal disease. Int Urol Nephrol 2011; 43 (2): 441-449.
Ogino K., Kato M., Furuse Y. et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010; 3: 73-81.
Miao Y., Ottenbros S.A., Laverman G.D. et al. Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial. Hypertension 2011; 58 (1): 2-7.
Gaffo A.L., Saag K.G. Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Core Evid 2010; 4: 25-36.
Alekseeva L.A., Popova L.A., Ryzhenkova I.V. Essentsial'naya arterial'naya gipertoniya i khronicheskaya pochechnaya nedostatochnost' u patsientov, dlitel'no nablyudayushchikhsya v mnogoprofil'nom meditsinskom uchrezhdenii. Klin nefrol 2010; 1: 49-52.

Close metadata